Depatuxizumab
Depatuxizumab Basic information
- Product Name:
- Depatuxizumab
- Synonyms:
-
- Depatuxizumab
- Research Grade Depatuxizumab (DHB86908)
- Research Grade Depatuxizumab
- Depatuxizumab (anti-EGFR)
- CAS:
- 1471999-69-5
- MW:
- 0
- Mol File:
- Mol File
Depatuxizumab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Depatuxizumab Usage And Synthesis
Uses
Depatuxizumab is a brain-penetrant and humanized tumor-specific anti EGFR monoclonal antibody. Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR. Depatuxizumab can be used for research on cancer[1].
in vivo
Depatuxizumab (10, 40 mg/kg, i.p., three times a week for 2 weeks) inhibits tumor growth significantly in U87MGde2-7 glioblastoma multiforme (GBM) models and A431 squamous xenograft models of Nu/Nu mice[1].
Depatuxizumab (10, 40 mg/kg, i.p., three times a week for 2 weeks) inhibits tumor growth and pEGFR levels in EGFRvIII-positive GBM SN0199 PDX models of NSG mice[1].
Depatuxizumab (2-40 mg/kg, i.p., three times a week for 2 weeks) inhibits tumor growth with dose dependent manner in SCC15 xenograft models of SCID Beige mice[1].
| Animal Model: | U87MGde2-7 glioblastoma multiforme (GBM) model of Nu/Nu mice[1] |
| Dosage: | 10, 40 mg/kg, three times a week for 2 weeks |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: | Inhibited tumor growth significantly more than Cetuximab (HY-P9905). Promoted a significant increase in TGI (tumor growth inhibition) when it combined with Temozolomide (HY-17364). |
| Animal Model: | EGFRvIII-positive GBM SN0199 PDX model, 3 to 5 mm3 passage 3 (P3) tumor fragments were s.c. trochar implanted in the right rear flank of NSG mice[1] |
| Dosage: | 10, 40 mg/kg, three times a week for 2 weeks |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: | Inhibited tumor growth significantly and reduced levels of pEGFR. |
| Animal Model: | A431 squamous xenograft model of Nu/Nu mice[1] |
| Dosage: | 10, 40 mg/kg, three times a week for 2 weeks |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: | Inhibited tumor growth with comparable activity to Cetuximab (HY-P9905) dosed in an equivalent manner at 10 mg/kg. Inhibited tumor growth by 58% at 40 mg/kg. |
| Animal Model: | SCC15 xenograft model of SCID Beige mice[1] |
| Dosage: | 2, 10, 20, 40 mg/kg, three times a week for 2 weeks |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: | Inhibited tumor growth with dose manner. Reduced the level of pEGFR and total EGFR in time-dependent. Reduced cell proliferation as measured by phospho-histone H3. Increased apoptosis as measured by caspase-3 cleavage. Increased antitumor activity when it was combined with both Cisplatin(HY-17394) or/and 5-FU(HY-90006) at 10 mg/kg. |
References
[1] Reilly EB, et al. Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. Mol Cancer Ther. 2015 May;14(5):1141-51. DOI:10.1158/1535-7163.MCT-14-0820
DepatuxizumabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
Depatuxizumab(1471999-69-5)Related Product Information
- Research Grade Clivatuzumab (DHD14205)
- Lupartumab
- Azintuxizumab
- Iscalimab
- Dilpacimab
- Nacolomabtafenatox
- Anumigilimab
- Etevritamab
- Immunoglobulin G1,anti-(human CD19 (antigen)) (mouse monoclonal B43 g1-chain), disulfide with mouse monoclonal B43 k-chain, dimer, disulfide withprotein PAP (pokeweed antiviral) (9CI)
- Ascrinvacumab